CL2014003325A1 - Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer - Google Patents
Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimerInfo
- Publication number
- CL2014003325A1 CL2014003325A1 CL2014003325A CL2014003325A CL2014003325A1 CL 2014003325 A1 CL2014003325 A1 CL 2014003325A1 CL 2014003325 A CL2014003325 A CL 2014003325A CL 2014003325 A CL2014003325 A CL 2014003325A CL 2014003325 A1 CL2014003325 A1 CL 2014003325A1
- Authority
- CL
- Chile
- Prior art keywords
- hexahydro
- difluoro
- cyclopentaoxacinyls
- benzooxacinyls
- bace
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 229940125759 BACE1 protease inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12173690 | 2012-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014003325A1 true CL2014003325A1 (es) | 2015-04-24 |
Family
ID=48672630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014003325A CL2014003325A1 (es) | 2012-06-26 | 2014-12-05 | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9181232B2 (es) |
| EP (1) | EP2864324B1 (es) |
| JP (1) | JP6251257B2 (es) |
| KR (1) | KR20150023450A (es) |
| CN (1) | CN104470915B (es) |
| AU (1) | AU2013283524B2 (es) |
| BR (1) | BR112014029742A2 (es) |
| CA (1) | CA2872181A1 (es) |
| CL (1) | CL2014003325A1 (es) |
| CO (1) | CO7151509A2 (es) |
| CR (1) | CR20140528A (es) |
| EA (1) | EA025273B1 (es) |
| IL (1) | IL236138A (es) |
| MA (1) | MA37763B1 (es) |
| MX (1) | MX2014014937A (es) |
| NZ (1) | NZ702253A (es) |
| PE (1) | PE20142450A1 (es) |
| PH (1) | PH12014502623A1 (es) |
| SG (1) | SG11201407576YA (es) |
| UA (1) | UA113309C2 (es) |
| WO (1) | WO2014001228A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA020740B1 (ru) | 2008-06-13 | 2015-01-30 | Шионоги & Ко., Лтд. | Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы |
| TWI488852B (zh) | 2009-12-11 | 2015-06-21 | Shionogi & Co | 衍生物 |
| WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
| WO2014134341A1 (en) | 2013-03-01 | 2014-09-04 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| CN105164121A (zh) | 2013-03-08 | 2015-12-16 | 美国安进公司 | 作为β分泌酶抑制剂的全氟化环丙基稠合的1,3-噁嗪-2-胺化合物以及其使用方法 |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
| MX381482B (es) | 2014-08-08 | 2025-03-12 | Amgen Inc | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso. |
| MX2017012188A (es) | 2015-03-20 | 2017-12-15 | Hoffmann La Roche | Inhibidores de beta-secretasa 1 (bace1). |
| JP7353708B2 (ja) * | 2018-04-27 | 2023-10-02 | 塩野義製薬株式会社 | 選択的ｂａｃｅ１阻害活性を有するテトラヒドロピラノオキサジン誘導体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102186841A (zh) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| TWI488852B (zh) * | 2009-12-11 | 2015-06-21 | Shionogi & Co | 衍生物 |
| UA103272C2 (uk) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
-
2013
- 2013-06-24 SG SG11201407576YA patent/SG11201407576YA/en unknown
- 2013-06-24 CN CN201380033783.7A patent/CN104470915B/zh not_active Expired - Fee Related
- 2013-06-24 PE PE2014002406A patent/PE20142450A1/es not_active Application Discontinuation
- 2013-06-24 BR BR112014029742A patent/BR112014029742A2/pt not_active IP Right Cessation
- 2013-06-24 UA UAA201500578A patent/UA113309C2/uk unknown
- 2013-06-24 EP EP13730887.0A patent/EP2864324B1/en not_active Not-in-force
- 2013-06-24 WO PCT/EP2013/063086 patent/WO2014001228A1/en not_active Ceased
- 2013-06-24 US US14/406,289 patent/US9181232B2/en not_active Expired - Fee Related
- 2013-06-24 CA CA2872181A patent/CA2872181A1/en not_active Abandoned
- 2013-06-24 NZ NZ702253A patent/NZ702253A/en not_active IP Right Cessation
- 2013-06-24 KR KR20147036016A patent/KR20150023450A/ko not_active Withdrawn
- 2013-06-24 EA EA201590066A patent/EA025273B1/ru not_active IP Right Cessation
- 2013-06-24 MA MA37763A patent/MA37763B1/fr unknown
- 2013-06-24 JP JP2015519008A patent/JP6251257B2/ja not_active Expired - Fee Related
- 2013-06-24 AU AU2013283524A patent/AU2013283524B2/en not_active Expired - Fee Related
- 2013-06-24 MX MX2014014937A patent/MX2014014937A/es unknown
-
2014
- 2014-11-18 CR CR20140528A patent/CR20140528A/es unknown
- 2014-11-24 PH PH12014502623A patent/PH12014502623A1/en unknown
- 2014-12-05 CL CL2014003325A patent/CL2014003325A1/es unknown
- 2014-12-08 IL IL236138A patent/IL236138A/en not_active IP Right Cessation
- 2014-12-10 CO CO14271199A patent/CO7151509A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015521640A (ja) | 2015-07-30 |
| US9181232B2 (en) | 2015-11-10 |
| AU2013283524A1 (en) | 2014-11-13 |
| US20150133440A1 (en) | 2015-05-14 |
| MA37763B1 (fr) | 2017-05-31 |
| AU2013283524B2 (en) | 2017-03-30 |
| PH12014502623B1 (en) | 2015-01-21 |
| EA025273B1 (ru) | 2016-12-30 |
| CR20140528A (es) | 2015-01-12 |
| CN104470915B (zh) | 2019-07-26 |
| PE20142450A1 (es) | 2015-01-28 |
| MA37763A1 (fr) | 2016-08-31 |
| IL236138A (en) | 2016-10-31 |
| CN104470915A (zh) | 2015-03-25 |
| MX2014014937A (es) | 2015-03-09 |
| IL236138A0 (en) | 2015-02-01 |
| NZ702253A (en) | 2016-06-24 |
| JP6251257B2 (ja) | 2017-12-20 |
| CO7151509A2 (es) | 2014-12-29 |
| SG11201407576YA (en) | 2015-03-30 |
| UA113309C2 (xx) | 2017-01-10 |
| WO2014001228A1 (en) | 2014-01-03 |
| CA2872181A1 (en) | 2014-01-03 |
| EP2864324B1 (en) | 2018-03-28 |
| EA201590066A1 (ru) | 2015-04-30 |
| HK1206344A1 (en) | 2016-01-08 |
| PH12014502623A1 (en) | 2015-01-21 |
| EP2864324A1 (en) | 2015-04-29 |
| KR20150023450A (ko) | 2015-03-05 |
| BR112014029742A2 (pt) | 2017-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE053113T2 (hu) | Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra | |
| CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| IL253225A0 (en) | Sulfamoyl-arylamides and their use as drugs to treat jaundice b | |
| CL2013001654A1 (es) | Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
| SI2935303T1 (sl) | 4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV | |
| CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| IL231536A (en) | Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases | |
| CL2014001090A1 (es) | Compuestos derivados de oxazolidinona biciclica; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como aterosclerosis y dislipidemia. | |
| CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
| IL235923B (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof | |
| CL2014002557A1 (es) | Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras. | |
| CL2014001838A1 (es) | Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras. | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| CL2015001342A1 (es) | Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer. | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| GB2497453B8 (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| CL2014001959A1 (es) | Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer. | |
| GB201511770D0 (en) | Novel pharmaceutical formulationsand their use in the treatment of periodontal disease | |
| CL2014003607A1 (es) | Compuestos derivados de benzodioxol, inhibidores de la acetilcolinesterasa; metodo de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o el tratamiento de la enfermedad de alzheimer. | |
| CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
| CL2013001445A1 (es) | Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer. | |
| LT2872145T (lt) | Sujungti benzazepinai tureto sindromui gydyti | |
| BR112015006272A2 (pt) | ''uso cosmético, composto, composição cosmética e método de tratamento cosmético'' |